Venus Remedies launches its flagship R&D drug Elores in Oman
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
Subscribe To Our Newsletter & Stay Updated